ArticleInternational journal of clinical and experimental pathology2025
Ploidy status analysis in small cell lung cancer cells and its use in cytopathological diagnosis.
Article in International journal of clinical and experimental pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the characteristics of the ploidy status of Small Cell Lung Cancer (SCLC) cells and assesses its efficacy in cytopathological diagnosis of SCLC.
methodsA retrospective analysis was performed on patients who agreed to DNA image cytometry (DNA ICM) and serum tumor biomarker testing. Samples for ploidy assessment, all from bronchial procedures, were analyzed using DNA ICM. Data on demographic features, pathological characteristics, staging results, biomarkers such as neuron specific enolase (NSE) and Pro-gastrin-releasing peptide (ProGRP) data, and ploidy status across different groups were collected. Corresponding statistical analyses were conducted to examine differences in aneuploid status among the groups. Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic efficacy of DNA ICM and tumor markers for diagnosing SCLC.
resultsA total of 74 patients with SCLC, 108 patients with NSCLC, and 74 patients with benign lesions were included. The age range of all patients was 26 to 85 years, with 69% being male and 31% female. In terms of ploidy status, single aneuploid cell peaks and double aneuploid peaks were observed in both SCLC and NSCLC groups. The proportions of two types of aneuploid cell peaks differed significantly between the two groups (
conclusionAneuploid cell peaks in SCLC patients are mostly distributed in the near triploid range, possibly serving as a specific cytological marker for SCLC. DNA ICM is a highly sensitive tool that may be an adjunct for SCLC diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.